P
HRTX icon

&Partners’s Heron Therapeutics HRTX Stock Holding History

&Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1K Buy
23,632
+705
+3% +$565 ﹤0.01% 2508
2026
Q1 		$18.3K Buy
+22,927
New +$26.6K ﹤0.01% 2382

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

&Partners's HRTX Position: Q2 2026 in Review

&Partners increased its Heron Therapeutics (HRTX) stake by 3.1% in Q2 2026, buying an estimated $565 and bringing the position to 23,632 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2508.

&Partners first reported a position in HRTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $18.3K in Q1 2026. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • &Partners held 23,632 shares of Heron Therapeutics worth $10.1K as of Q2 2026.
  • &Partners bought 705 Heron Therapeutics shares in Q2 2026, an estimated $565.
  • Heron Therapeutics made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2508 holding.
  • &Partners first reported a position in Heron Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • &Partners's Heron Therapeutics position peaked at $18.3K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.